- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00413400
Study of TNF-Antagonism in the Metabolic Syndrome (II)
3 de noviembre de 2010 actualizado por: Massachusetts General Hospital
Effects of Etanercept in Patients With the Metabolic Syndrome (II)
This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Metabolic syndrome is an increasingly prevalent disorder associated with elevated risks of type II DM (diabetes mellitus) and cardiovascular morbidity and mortality.
A subclinical inflammatory state is thought to contribute to the pathophysiology of metabolic syndrome, insulin resistance, and coronary artery disease (CAD).
Tumor Necrosis Factor (TNF) -alpha is an inflammatory cytokine that is increased in a spectrum of inflammatory diseases as well as in insulin resistance.
TNF-alpha antagonists are clinically effective in the inflammation of arthritides, and have recently been shown by our group to decrease inflammatory cardiovascular risk markers in metabolic syndrome.
Data suggests that adiponectin, a recently discovered adipocytokine that may protect against the development of insulin resistance and atherosclerosis, may be downregulated by TNF-alpha.
In addition, population based studies have shown that those with the highest levels of TNF-alpha have an increased relative risk of cardiovascular morbidity while rheumatoid arthritis patients treated with TNF-alpha blockade appear protected from cardiovascular disease.
We will perform a 6-month study in which we will administer etanercept, a TNF-alpha receptor fusion protein, to subjects with metabolic syndrome to investigate its effect on surrogate markers of cardiovascular disease, including inflammatory markers, adiponectin and glucose tolerance and endothelial function.
The results of the proposed study will have broad implications regarding the physiological role of TNF-alpha on the inflammatory cascade, cardiovascular indices and endothelial function.
Tipo de estudio
Intervencionista
Inscripción (Actual)
40
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- MGH
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 60 años (Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Hyperinsulinemia in the upper quartile of the non-diabetic population defined as >= 10 mU/mL (based on Framingham Data, oral communication, James Meigs, MD) or fasting glucose 110-126 mg/dL
Plus two of the following:
- Abdominal obesity defined by waist hip ratio > 0.90 for men and > 0.85 for women and BMI > 30 kg/m2
- Dyslipidemia including serum triglycerides >= 150 mg/dl or serum high density lipoprotein (HDL) < 0.9 mmol/L for men (35 mg/dL) and < 1.0 mmol/L (39mg/dL) for women
- Hypertension defined as blood pressure >= 140/90 or on medication
Exclusion Criteria:
- Age < 18 or > 60 years
- Body mass index (BMI) < 30 kg/m2
- Positive tuberculosis (purified protein derivative [PPD]) skin test (5mm induration or more) on screening
- Mycobacterial disease treated less than 6 months.
- Current or recurrent infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection.
- Therapy with glucocorticoid or immunosuppressant at time of recruitment or within past 3 months.
- Prior or concurrent cyclophosphamide therapy
- Use of a live vaccine 90 days prior to, or during this study.
- History of blood dyscrasia including any kind of anemia, thrombocytopenia, pancytopenia. Women with a reversible cause of anemia that has resolved will be eligible.
- Hemoglobin < 11 g/dl
- History of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers who will be eligible)
- History of organ transplantation
- HIV-positive status determined by HIV test at screening or known history of any other immuno-suppressing disease.
- Hepatitis B or hepatitis C infection detected at screening, lupus (SLE), history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
- Patients with known autoimmune or inflammatory conditions (excluding patients with stable, treated hypothyroidism)
- Severe comorbidities (diabetes mellitus requiring insulin, congestive heart failure (CHF) (EF<50% at baseline will be exclusionary) of any severity, myocardial infarction (MI), cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease
- Uncontrolled systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg
- Fasting blood glucose > 126 mg/dL
- Creatinine > 1.5
- Current use of insulin, any oral anti-hyperglycemic agents (including insulin sensitizing agents). Initiation of insulin, oral hypoglycemics, or insulin sensitizing agents during the study will result in discontinuation from the study.
- Initiation of statins, niacin, antihypertensive or fibrate therapy within 6 weeks of the study. Chronic use of fibrates, niacin, or antihypertensives for > 6 weeks prior to study initiation at a stable dose is not exclusionary, but chronic use of statins for > 6 months is exclusionary. Initiation of statins, fibrates, niacin or antihypertensive treatments during the study is not exclusionary but will be considered in the analysis (see Protection against risks).
- Positive pregnancy test or lactating females
- Women of child-bearing potential not currently using non-hormonal birth control methods including barrier methods (intrauterine device [IUD], condoms, diaphragms) or abstinence
- Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
- Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept
- Concurrent sulfasalazine therapy
- History of recent alcohol or substance abuse (< 1 year)
- Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient.
- History of non-compliance with other therapies
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
|
50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
|
|
Comparador activo: Etanercept
|
50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
C-reactive Protein (CRP)
Periodo de tiempo: 6 months
|
As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported
|
6 months
|
|
Interleukin-6 (IL-6)
Periodo de tiempo: 6 months
|
6 month value of IL-6 (pg/mL)
|
6 months
|
|
Adiponectin
Periodo de tiempo: 6 months
|
The ratio of circulating high molecular weight (HMW) adiponectin to total adiponectin ratio (HMW:total Adiponectin) at 6 months is reported.
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Glucose Tolerance
Periodo de tiempo: 6 months
|
Fasting glucose (mg/dL) at 6mo
|
6 months
|
|
Endothelial Function
Periodo de tiempo: 6 months
|
Reactive Hyperemia Index (RHI) using peripheral artery tonometry (using Endo-PAT 2000).
Peripheral artery tonometry measures blood flow in the tip of the index finger at baseline and in response to vaso-occlusion (inflated blood pressure cuff).
The reactive hyperemia index is an index of vasodilation after occlusion compared to baseline.
A higher value indicates better vasoreactivity.
As this is a relatively new test, there are no thoroughly validated clinically utilized norms.
|
6 months
|
|
White Blood Cell (WBC) Count
Periodo de tiempo: Baseline to 6 months
|
Change in WBC during study (WBC at six months minus WBC at baseline)
|
Baseline to 6 months
|
|
Cardiac Echo Ejection Fraction (EF)
Periodo de tiempo: Baseline to 6 months
|
change in EF (6mo - baseline).
Please note that the value given is the absolute change in EF (which has units of percent), not the percent change in the variable.
|
Baseline to 6 months
|
|
Body Composition
Periodo de tiempo: 6 months
|
6 month visceral adipose tissue (cm^2) - cross-sectional area of the visceral adipose tissue at the level of the 4th lumbar vertebrae was measured using single-slice abdominal computed tomography (CT) scan
|
6 months
|
|
Tumor Necrosis Factor (TNF) Receptor
Periodo de tiempo: 6 months
|
Circulating concentrations of Tumor necrosis factor receptor 2 (TNFR2) at 6 months
|
6 months
|
|
Other Adipocytokines
Periodo de tiempo: 6 months
|
circulating resistin at 6 months
|
6 months
|
|
Lipid Levels
Periodo de tiempo: 6 months
|
total cholesterol (mg/dL) at 6 months
|
6 months
|
|
Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha
Periodo de tiempo: 6 months
|
fold-change in subcutaneous adipose tissue expression of TNF-alpha (mRNA) after 6 months
|
6 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Steven K Grinspoon, MGH
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de diciembre de 2006
Finalización primaria (Actual)
1 de septiembre de 2009
Finalización del estudio (Actual)
1 de septiembre de 2009
Fechas de registro del estudio
Enviado por primera vez
7 de diciembre de 2006
Primero enviado que cumplió con los criterios de control de calidad
18 de diciembre de 2006
Publicado por primera vez (Estimar)
19 de diciembre de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
2 de diciembre de 2010
Última actualización enviada que cumplió con los criterios de control de calidad
3 de noviembre de 2010
Última verificación
1 de noviembre de 2010
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Trastornos del metabolismo de la glucosa
- Enfermedades metabólicas
- Enfermedad
- Resistencia a la insulina
- Hiperinsulinismo
- Síndrome
- Síndrome metabólico
- Efectos fisiológicos de las drogas
- Agentes del sistema nervioso periférico
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes Gastrointestinales
- Etanercept
Otros números de identificación del estudio
- 2006-P-001060
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .